Inspire Medical Systems, Inc. financials

  1. Home
  2. Financials
  3. INSP
INSP CIK 0001609550

Source: EDGAR filings · Built 2026-06-02T03:18:31Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 78.48M 91.12M 1.02M 2.47M -24.79M -55.50M
EBITDA 64.91M 42.63M -37.42M -45.73M -38.63M -55.37M
Working Capital 487.60M 542.30M 515.63M 468.85M 227.23M 249.14M
Net Debt -72.66M -118.36M -160.69M -432.72M -171.67M -159.89M
Gross Margin 85.39% 84.68% 84.54% 83.79% 85.74% 84.73%
Operating Margin 5.59% 4.49% -6.45% -11.67% -17.07% -48.72%
Net Margin 15.95% 6.67% -3.39% -11.00% -18.01% -49.58%
Return on Equity (ROE) 18.62% 7.76% -3.69% -9.05% -18.36% -24.90%
Return on Assets (ROA) 16.03% 6.62% -3.13% -7.95% -14.25% -20.34%
Current Ratio 6.08× 7.13× 7.60× 8.66× 6.50× 13.02×
Debt-to-Equity 0.04× 0.05× 0.04× 0.02× 0.19× 0.13×
Effective Tax Rate -121.35% 8.46% -6.26% -1.38% -0.17% -0.20%
Cash Conversion Ratio 0.80× 2.43× -1.17× -0.26× 0.48× 0.93×
Accruals Ratio 0.03× -0.09× -0.07× -0.10× -0.07× -0.01×
SBC % of Revenue 14.28% 14.45% 13.20% 12.74% 11.22% 11.11%
CapEx Coverage 3.04× 3.33× 1.04× 1.27× -4.31× -21.61×
Free Cash Flow Per Share $2.64 $2.98 $0.03 $0.09 $-0.91 $-2.13

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 18.86× 105.93× — — — —
P/FCF 34.97× 62.14× 5828.94× 2859.02× — —
FCF Yield 2.86% 1.61% 0.02% 0.04% — —
EV / EBITDA 39.49× 126.54× — — — —
P/S 2.89× 6.87× 9.62× 17.91× 27.02× 44.13×
P/B 3.37× 7.99× 10.50× 14.73× 27.54× 22.16×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 911.98M 802.80M 624.80M 407.86M 233.39M 115.38M
Cost of Goods and Services Sold 133.22M 122.99M 96.58M 66.11M 33.28M 17.62M
Gross Profit 778.76M 679.82M 528.22M 341.74M 200.12M 97.76M
Research and Development Expense 103.17M 114.13M 116.54M 68.64M 37.35M 26.09M
Selling, General and Administrative Expense 624.64M 529.61M 451.96M 320.69M 202.62M 127.87M
Operating Expenses — — 568.49M 389.33M 239.97M 153.97M
Operating Income (Loss) 50.95M 36.08M -40.27M -47.59M -39.85M -56.21M
Income Tax Expense (Benefit) -79.72M 4.94M 1.25M 613.00K 72.00K 115.00K
Net Income (Loss) Attributable to Parent 145.42M 53.51M -21.15M -44.88M -42.04M -57.20M
Earnings Per Share, Basic $4.95 $1.80 $-0.72 $-1.60 $-1.54 $-2.19
Weighted Average Number of Shares Outstanding, Basic 29.37M 29.76M 29.30M 28.07M 27.26M 26.07M
Earnings Per Share, Diluted $4.89 $1.75 $-0.72 $-1.60 $-1.54 $-2.19
Weighted Average Number of Shares Outstanding, Diluted 29.76M 30.54M 29.30M 28.07M 27.26M 26.07M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 104.81M 150.15M 185.54M 441.59M 214.47M 190.52M
Assets, Current 583.65M 630.81M 593.74M 530.03M 268.54M 269.87M
Assets 907.32M 808.38M 676.81M 564.88M 295.08M 281.19M
Long-term Debt — — — — 24.50M 24.50M
Liabilities, Current 96.06M 88.50M 78.11M 61.19M 41.31M 20.73M
Liabilities 126.16M 118.69M 104.30M 68.87M 66.04M 51.44M
Stockholders' Equity Attributable to Parent 781.16M 689.70M 572.51M 496.01M 229.05M 229.75M
Common Stock, Shares, Outstanding 28.58M 29.74M 29.56M 29.01M 27.42M 27.07M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 116.98M 130.25M 24.65M 11.57M -20.12M -53.05M
Payments to Acquire Property, Plant, and Equipment 38.50M 39.12M 23.63M 9.10M 4.67M 2.46M
Net Cash Provided by (Used in) Investing Activities 21.45M -113.12M -294.82M -19.60M 29.14M 86.63M
Payments for Repurchase of Common Stock 175.02M 0 0 0 — —
Net Cash Provided by (Used in) Financing Activities -183.45M -52.39M 13.95M 235.08M 14.95M 134.06M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (INSP CIK 0001609550), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

VOR

VOR BIOPHARMA INC.

DOUG

DOUGLAS ELLIMAN INC.

NDSN

NORDSON CORPORATION